Moxonidin Actavis (Moxonidine)

Moxonidine selectively activates central imidazoline I1 receptors, reducing sympathetic nervous system outflow. This leads to decreased peripheral vascular resistance and lower cardiac output, resulting in a sustained reduction of arterial blood pressure without directly affecting heart contractility.

The dosage of Moxonidin Actavis is individualized by the prescribing clinician based on the patient’s blood pressure, renal function, and response to therapy. The prescriber determines the appropriate starting dose and any subsequent titration.

The safety of moxonidine in pregnancy and lactation has not been definitively established. It is generally advised to avoid use unless the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To request Moxonidin Actavis, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Moxonidine belongs to the imidazoline receptor agonist class, offering a central mechanism distinct from ACE inhibitors, ARBs, calcium‑channel blockers, or beta‑blockers. It is particularly useful when patients need additional blood‑pressure reduction without significant effects on heart rate or metabolic parameters.

Moxonidin Actavis tablets should be stored at ambient temperature below 25 °C, in the original packaging, and protected from moisture and direct sunlight. Do not store in a refrigerator or freezer.

Moxonidin Actavis is taken orally, usually with or without food, as directed by the prescribing physician. The tablet should be swallowed whole with a glass of water and not chewed or crushed unless specifically instructed.

Serious risks include severe hypotension, bradycardia, and rare allergic reactions such as rash, swelling, or breathing difficulty. Patients should seek immediate medical attention if they experience symptoms of a significant drop in blood pressure or an allergic response.

Moxonidin Actavis is contraindicated in patients with known hypersensitivity to moxonidine or any excipients in the formulation. Caution is advised for individuals with severe renal impairment, uncontrolled heart failure, or those taking other central sympatholytic agents.